en
Scientific article
Open access
English

Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance

Published inTherapeutic Drug Monitoring, vol. 40, no. 1, p. 84-92
Publication date2018
Abstract

Busulfan (Bu) is an alkylating agent used as part of the conditioning regimen in pediatric patients before hematopoietic stem cell transplantation. Despite intravenous (IV) administration and dosing recommendations based on age and weight, reports have revealed interindividual variability in Bu pharmacokinetics and the outcomes of hematopoietic stem cell transplantation. In this context, adjusting doses to Bu's narrow therapeutic window is advised. We aimed to assess the utility of therapeutic drug monitoring (TDM) of Bu in children, the reliability of Bu quantification methods, and its stability in plasma when stored for up to 5 years.

Keywords
  • Alkylating Agents/blood/pharmacokinetics
  • Busulfan/blood/pharmacokinetics
  • Child
  • Chromatography, High Pressure Liquid/methods
  • Dose-Response Relationship, Drug
  • Drug Monitoring/methods
  • Drug Stability
  • Hematopoietic Stem Cell Transplantation/methods
  • Humans
  • Quality Control
  • Reproducibility of Results
  • Tandem Mass Spectrometry/methods
  • Time Factors
Citation (ISO format)
CHOONG, Eva et al. Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance. In: Therapeutic Drug Monitoring, 2018, vol. 40, n° 1, p. 84–92. doi: 10.1097/FTD.0000000000000468
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0163-4356
718views
333downloads

Technical informations

Creation11/13/2018 3:41:00 PM
First validation11/13/2018 3:41:00 PM
Update time03/15/2023 3:08:21 PM
Status update03/15/2023 3:08:20 PM
Last indexation02/12/2024 11:36:25 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack